Popular on Rezul
- SureFlow to Showcase AI and Eco-Technology Energy Management Solutions at GITEX 2024 - 139
- Origination of Prince Oak's new alias and reasons of his change — the Eurasian Prince's newest nominal label is "Papa Eurasia"
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- Bug Busters Celebrates 40 Years in the Pest Control Industry
- Chambliss Mortgage Capital Launches Initiative to Empower Real Estate Investors& Reduce Homelessness
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
- EFLOW FX Pioneers Tokenized Real Estate for Greater Accessibility and Growth
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- Berkshire Hathaway HomeServices FNR President Ann King receives 2024 Ultimate CEO Award
Similar on Rezul
- Qualis welcomes Steven C. Miley as Vice President of Contracts
- Coker Announces Acquisition of Healthcare Consulting Firm, TTG Healthcare Advisors
- Paul Ormsby is appointed by STS Capital Partners as Senior Vice President of Operations
- Nexgen Outfitters Secures GSA Contract, Bringing Premier Outdoor Sporting Goods and Equipment to Federal, State, and Local Agencies
- Capital Realty Group Has An Outstanding October!
- Healthcare Consulting Firm, Coker, Announces Acquisition of NorthGauge Healthcare Advisors
- Drive for Gratitude Significantly Impacts Veterans Well-being
- Allegiant Management Group's Alex Zweydoff, RMP®, Receives 2024 Darrell Kazen Memorial Scholarship at 2024 NARPM® National Convention
- From Tax Advisor to Community Advocate
- Upcoming Webinar: Family-Owned Businesses in Italy and Spain: Opportunities and Pitfalls for International Investors
Saol Therapeutics Announces Positive Topline Results from the SL-1002 RAISE Limb Spasticity Trial
Rezul News/10684281
~ Saol Therapeutics, a clinical-stage pharmaceutical company, has recently announced positive results from its SL-1002 RAISE Limb Spasticity Trial. The data was presented at the Spasticity X Symposium in Houston, Texas by Dr. Sheng Li and Dr. Gerard Francisco.
The trial focused on the safety and efficacy of SL-1002, a novel chemoneurolytic injection utilizing Saol's proprietary CYCLOPHLEX™ technology. It was a double-blind, vehicle-controlled study that included 32 patients with mild to severe limb spasticity. The primary endpoint was to evaluate the overall safety profile of SL-1002 compared to the vehicle.
The results showed that SL-1002 was well-tolerated with no therapy or program-limiting adverse events reported. Out of the 32 patients, 24 received SL-1002 while 8 received the vehicle. Five serious adverse events (SAEs) were reported but were determined by investigators to be unrelated to the treatment. Fourteen non-serious treatment-emergent adverse events (TEAEs) were observed and considered mild by investigators.
More on Rezul News
The secondary endpoints included assessments using the Modified Ashworth Scale (MAS), which is commonly used in spasticity trials. Despite not being powered for efficacy, SL-1002 showed a statistically significant improvement over the vehicle at multiple time points throughout the trial. At 6 months, there was a significant reduction in MAS compared to baseline in the SL-1002 arm (-1.18) compared to the vehicle arm (-0.33).
Dave Penake, CEO of Saol Therapeutics, expressed his excitement about these positive results and acknowledged the need for new treatment options for spasticity. He also highlighted the strong safety profile observed in this trial and the long-lasting efficacy of SL-1002.
Penake also thanked all those involved in making this trial possible, including patients, investigators, and clinical trial site teams. He emphasized their collaboration and commitment as the driving force behind medical progress.
More on Rezul News
Dr. Gerard Francisco, the Principal Investigator for the trial, commented on the urgent need for more innovative therapies to treat spasticity. He also noted that these early results show that SL-1002 is safe, effective, and durable.
The RAISE Limb Spasticity Trial was conducted at UTHealth Houston in Houston, TX, and the Medical College of Wisconsin in Milwaukee, WI. Saol Therapeutics plans to meet with the FDA in the first half of 2025 to determine the next steps for SL-1002 in its spasticity program.
In addition to limb spasticity, SL-1002 is also being investigated for its potential to treat pain related to osteoarthritis of the knee in the COMPASS Osteoarthritis Knee Pain Trial. Results from this trial are yet to be released.
Saol Therapeutics is dedicated to developing innovative treatments for debilitating conditions like spasticity and osteoarthritis. With these positive results from their RAISE Limb Spasticity Trial, they are one step closer to providing much-needed relief for patients suffering from these conditions.
The trial focused on the safety and efficacy of SL-1002, a novel chemoneurolytic injection utilizing Saol's proprietary CYCLOPHLEX™ technology. It was a double-blind, vehicle-controlled study that included 32 patients with mild to severe limb spasticity. The primary endpoint was to evaluate the overall safety profile of SL-1002 compared to the vehicle.
The results showed that SL-1002 was well-tolerated with no therapy or program-limiting adverse events reported. Out of the 32 patients, 24 received SL-1002 while 8 received the vehicle. Five serious adverse events (SAEs) were reported but were determined by investigators to be unrelated to the treatment. Fourteen non-serious treatment-emergent adverse events (TEAEs) were observed and considered mild by investigators.
More on Rezul News
- The Pros and Cons of Buying Condos and Townhomes in Central Florida
- Join the Exclusive Webinar on AI Transformation in Real Estate Financing
- Never-Before-Seen Kamala Harris and Ady Barkan Interview Released on Anniversary of Barkan's Passing, Just Ahead of Election Day
- Hoodgeek Merges Pov Commentary On Culture, Entertainment, Politics, Music, Sports, And Technology
- Boot Scootin' for Scholarships: A Night of Music, Dancing, and Giving Back!
The secondary endpoints included assessments using the Modified Ashworth Scale (MAS), which is commonly used in spasticity trials. Despite not being powered for efficacy, SL-1002 showed a statistically significant improvement over the vehicle at multiple time points throughout the trial. At 6 months, there was a significant reduction in MAS compared to baseline in the SL-1002 arm (-1.18) compared to the vehicle arm (-0.33).
Dave Penake, CEO of Saol Therapeutics, expressed his excitement about these positive results and acknowledged the need for new treatment options for spasticity. He also highlighted the strong safety profile observed in this trial and the long-lasting efficacy of SL-1002.
Penake also thanked all those involved in making this trial possible, including patients, investigators, and clinical trial site teams. He emphasized their collaboration and commitment as the driving force behind medical progress.
More on Rezul News
- Brett Furman Group Launches Ready-Set-Sell Program
- Alaskan Artist Builds Business to Fight Global Exploitation Through Fashion
- John Atencio Hosts Legacy Of Love Bridal & Diamond Event This November
- Dogma Systems lanza Security@Dogma: Solución Integral para la Seguridad de la Información
- New Construction in Mora built by local builder Heartland Homes
Dr. Gerard Francisco, the Principal Investigator for the trial, commented on the urgent need for more innovative therapies to treat spasticity. He also noted that these early results show that SL-1002 is safe, effective, and durable.
The RAISE Limb Spasticity Trial was conducted at UTHealth Houston in Houston, TX, and the Medical College of Wisconsin in Milwaukee, WI. Saol Therapeutics plans to meet with the FDA in the first half of 2025 to determine the next steps for SL-1002 in its spasticity program.
In addition to limb spasticity, SL-1002 is also being investigated for its potential to treat pain related to osteoarthritis of the knee in the COMPASS Osteoarthritis Knee Pain Trial. Results from this trial are yet to be released.
Saol Therapeutics is dedicated to developing innovative treatments for debilitating conditions like spasticity and osteoarthritis. With these positive results from their RAISE Limb Spasticity Trial, they are one step closer to providing much-needed relief for patients suffering from these conditions.
Filed Under: Business
0 Comments
Latest on Rezul News
- Advisors Mortgage Group Celebrates 25 Years of Building Dreams and Strengthening Communities
- SOVAS Honors the Legacy of James Earl Jones With the Newly Established "The James Earl Jones Prize"
- Nayarit Becomes An Official Tourism Destination of the Los Angeles Lakers
- David Weekley Homes Scored Nine Trophies at The 2024 Atlanta Obie Awards
- Nexgen Outfitters Secures GSA Contract, Bringing Premier Outdoor Sporting Goods and Equipment to Federal, State, and Local Agencies
- Raleigh-Wake County Parade of Homes Winners Announced
- Onestreet Residential Closes On Hearthside Riverdale Site
- Transform Your Date Night with Lick Pineapple Flavored Massage Oil – The Perfect Gift for New Relationships
- Alessia Moccia of E-uphoria: Bridging Fashion, Art, and Technology in NYC
- The Nature Conservancy, Partners Protect Water for People and Nature with Landmark Easement
- Attorney Eric Chun Joins Bisnar Chase Personal Injury Attorneys, LLP
- Capital Realty Group Has An Outstanding October!
- The United States Environmental Protection Agency (USEPA) is SEBAC's 2024 Award for Excellence winner
- TrailMark hosting Groove in the Grove Music Festival on Nov. 16
- Author Riley G. Staliger Offers Tools to Escape Guilt-Driven Relationships AKA Obligationships Using Pop Culture
- Healthcare Consulting Firm, Coker, Announces Acquisition of NorthGauge Healthcare Advisors
- Kaplan Morrell Named Exclusive Workers' Compensation Firm for Greeley Fire Fighters
- Drive for Gratitude Significantly Impacts Veterans Well-being
- The Voice of the Wooden Dragon is Latest Release from NFB Publishing
- AONE Fest 2024: Celebrating Creativity and Community at Red Dot Studios